Breakthrough Science for Severe Viral Lung Infections
We are a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta (IFN-β) for the treatment of severe viral lung infections as potentially the first host-directed, broad-spectrum antiviral treatment delivered directly into the lungs.
Not All Antivirals Are the Same
Host Directed, broad-spectrum antivirals
Host Directed is Synairgen's new podcast series that explores the need for broad-spectrum antivirals to treat severe respiratory infections. In Episode 1, Not All Antivirals Are the Same, Professor Tom Wilkinson from the University of Southampton and Vicki Tear, Vice President, Non-Clinical Operations, Synairgen, discuss how antiviral agents work on viruses and the potential benefits of broad-spectrum host-directed antivirals. Episode 2 includes Professor Ratko Djukanovic, Professor of Medicine at University of Southampton and Richard Marsden, CEO of Synairgen, continuing the discussion with a focus on understanding the broad-spectrum antiviral protein, IFN-β.
Episode 1: Not All Antivirals Are the Same
Professor Tom Wilkinson from the University of Southampton and Vicki Tear, Vice President, Non-Clinical Operations, Synairgen, discuss how antiviral agents work on viruses and the potential benefits of broad-spectrum host-directed antivirals.
Episode 2: What is IFN-β and How Does It Work?
Professor Ratko Djukanovic, Professor of Medicine at University of Southampton and Richard Marsden, CEO of Synairgen, continue to explore antivirals with a discussion focused on understanding the broad-spectrum antiviral protein, IFN-β .
The Need
Viruses that cause severe respiratory infections (VRIs) lead to the hospitalisation of more than 3 million people in the US alone each year.
There are currently no broad-spectrum antivirals approved for use in patients who become hospitalised with these sRVIs including SARS-CoV-2, complicated influenza, RSV, adenovirus, parainfluenza and rhinoviruses.
source: IQVIA
Estimated 3m+
people in US hospitalised annually from 2022 onwards due to severe VRIs
source: IQVIA market research Q4 2022; Sources: US CDC, HCUP, IQVIA Claims Data, PubMed; data on file7m immuno-compromised
in the US, representing a population at significant risk for severe RVIs
source: American Medical Association$50b
The estimated annual US healthcare costs related to severe VRIs
sources: Hartnet J. Influenza Other Respi Viruses. 2022;16:906–915; Pastula ST et.al.,OFID, 2017,ofw270; Zhou JA et.al., CID, 2020, 70(5): 773-779; Disease Burden of Flu | CDC; Preliminary Medicare COVID-19 Data Snapshot (Dec 2021); ICER Report: Special Assessment of Outpatient Treatments for COVID-19 Feb 2022
It Ain’t Over Till It’s Over…but It’s Never Over
Dr. Anthony Fauci, New England Journal of Medicine, 26 November 2022